<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520726</url>
  </required_header>
  <id_info>
    <org_study_id>UUtahIRB0062412</org_study_id>
    <nct_id>NCT02520726</nct_id>
  </id_info>
  <brief_title>PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Pilot Study of Sertraline for the Prevention of PTSD in Burn Victims</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to determine whether
      administration of sertraline to patients who exhibit acute stress disorder secondary to
      severe burns can contribute to the prevention of post-traumatic stress disorder (PTSD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale Score</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Scale for Suicide Ideation</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age &gt;65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>&lt; 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.</description>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Victim of a traumatic event leading to personal injury

          -  Patient experienced a feeling of intense fear, hopelessness, or horror during the
             course of the event or immediately afterward

          -  Positive screen on the ASDS (for inclusion in the randomization phase); a total ASDS
             score of ≥ 37 (including a dissociative score of ≥ 9) will be counted as a positive
             screen.

        Exclusion Criteria:

          -  Age &lt; 18

          -  Pregnant women, lactating women, or women not using acceptable form of birth control

          -  Epilepsy or head trauma resulting in seizures

          -  Current or historical schizophrenia, bipolar disorder, mental retardation, OCD,
             eating disorders, dementia, delirium, or self-injurious behavior

          -  Current/previously diagnosed PTSD

          -  History of hypersensitivity to sertraline

          -  Trauma occurring &gt; 7 days prior to likely first treatment in the randomization phase
             of the trial.

          -  Unable to provide informed consent for participation in the study protocol.

          -  Patient at high risk of recurrent bleeding despite surgical stabilization

          -  Patient with a history of serotonin syndrome

          -  Patient non-fluent in English

          -  Patient currently prescribed an antidepressant (any SSRI, SNRI, TCA, MAOI,
             mirtazapine, or trazodone in excess of 100mg per day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent M Kious, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>April 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Brent Kious</investigator_full_name>
    <investigator_title>Psychiatry Resident</investigator_title>
  </responsible_party>
  <keyword>Posttraumatic stress disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Burns</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
